Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)

被引:126
|
作者
Stoiber, H
Pinter, C
Siccardi, AG
Clivio, A
Dierich, MP
机构
[1] INST HYG,A-6020 INNSBRUCK,AUSTRIA
[2] LUDWIG BOLTZMANN INST AIDS FORSCH,A-6020 INNSBRUCK,AUSTRIA
[3] UNIV MILAN,DIPARTIMENTO BIOL & GENET SCI MED,LAB INTERDISCIPLINARE TECHNOL AVANZATE VIALBA,I-20157 MILAN,ITALY
[4] DIPARTIMENTO BIOL & TECHNOL SAN RAFFAELE,I-20132 MILAN,ITALY
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 1996年 / 183卷 / 01期
关键词
D O I
10.1084/jem.183.1.307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activation of the human complement system leads to complement deposition on human immunodeficiency virus (HIV) and HIV-infected cells without causing efficient complement-mediated lysis. Even in the presence of HIV-specific antibodies, only a few particles are destroyed, demonstrating that HIV is intrinsically resistant to human complement. Here we report that, in addition to decay accelerating factor (DAF) being partially responsible, human complement factor H (CFH), a humoral negative regulator of complement activation, is most critical for this resistance. In the presence of HIV-specific antibodies, sera devoid of CFH (total genetic deficiency or normal human serum depleted of CFH by affinity chromatography) lysed free virus and HIV-infected but not uninfected cells. In the presence of CFH, lysis of HIV was only obtained when binding of CFH to gp41 was inhibited by a monoclonal antibody against a main CFH-binding site in gp41. Since CFH is an abundant protein in serum, and high local concentration of CFH can be obtained at the surface of HIV as the result of specific interactions of CFH with the HIV envelope, it is proposed that the resistance of HIV and HIV-infected cells against complement-mediated lysis in vivo is dependent on DAF and CFH and can be overcome by suppressing this protection. Neutralization of HIV may be achieved by antibodies against DAF and, more importantly, antibodies against CFH-binding sites on HIV envelope proteins.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 50 条
  • [1] Complement decay accelerating factor (DAF)/CD55 in cancer
    Spendlove, I
    Ramage, JM
    Bradley, R
    Harris, C
    Durrant, LG
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (08) : 987 - 995
  • [2] Complement decay accelerating factor (DAF)/CD55 in cancer
    Ian Spendlove
    Judith M. Ramage
    Richard Bradley
    Claire Harris
    Lindy G. Durrant
    Cancer Immunology, Immunotherapy, 2006, 55 : 987 - 995
  • [3] DECAY-ACCELERATING FACTOR (CD55) PROTECTS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM INACTIVATION BY HUMAN-COMPLEMENT
    MARSCHANG, P
    SODROSKI, J
    WURZNER, R
    DIERICH, MP
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (01) : 285 - 290
  • [4] EXPRESSION OF DECAY-ACCELERATING FACTOR (CD55) OF THE COMPLEMENT-SYSTEM ON HUMAN SPERMATOZOA
    CERVONI, F
    OGLESBY, TJ
    FENICHEL, P
    DOHR, G
    ROSSI, B
    ATKINSON, JP
    HSI, BL
    JOURNAL OF IMMUNOLOGY, 1993, 151 (02): : 939 - 948
  • [5] DEFICIENCY OF COMPLEMENT DECAY-ACCELERATING FACTOR (DAF, CD55) IN NON-HODGKINS-LYMPHOMA
    FUKUDA, H
    SEYA, T
    HARA, T
    MATSUMOTO, M
    KINOSHITA, T
    MASAOKA, T
    IMMUNOLOGY LETTERS, 1991, 29 (03) : 205 - 210
  • [6] Role of Decay accelerating factor (DAF; CD55) in pathophysiology of Rheumatoid Arthritis
    Pahwa, R.
    Kumar, U.
    Kanjilal, M.
    Das, N.
    IMMUNOLOGY, 2013, 140 : 20 - 20
  • [7] Activation of human monocytes via CD55 (decay accelerating factor)
    FitzGibbon, HJ
    Spendlove, I
    BRITISH JOURNAL OF CANCER, 2004, 91 : S74 - S74
  • [8] The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy
    Mikesch, Jan-Henrik
    Schier, Kathrin
    Roetger, Antje
    Simon, Ronald
    Buerger, Horst
    Brandt, Burkhard
    CELLULAR ONCOLOGY, 2006, 28 (5-6) : 223 - 232
  • [9] Progesterone Receptors Signaling and Upregulation of Decay-Accelerating Factor (DAF/CD55)
    Ansley, Ariel J.
    Rana, Tanu
    Nowicki, Stella
    Nowicki, Bogdan
    OBSTETRICS AND GYNECOLOGY, 2014, 123 : 135S - 136S
  • [10] Importance of Decay Accelerating Factor(CD55) in Tumor Avoidance of Immune Destruction
    Li, Bing
    Allendorf, Daniel
    Hansen, Richard
    Marroquin, Jose
    Cramer, Daniel
    Harris, Claire
    Yan, Jun
    JOURNAL OF IMMUNOLOGY, 2007, 178